---
title: "Sol-Gel Technologies (SLGL) news: offering and Nasdaq notice"
url: "https://aibio.space/companies/sol-gel-technologies/"
publisher: "aibio.space (Biotech Investor Relations News)"
summary: "SLGL offering and Nasdaq notice news: Sol-Gel says $33.1 million March offering and $52.8 million balance fund it into 2028. Sol-Gel Technologies Ltd."
---

SLGL Sol-Gel Technologies Ltd. NASDAQ · Israel

# Sol-Gel Technologies (SLGL) news SLGL offering and Nasdaq notice news

Financings · 2026-05-28

## [Sol-Gel says $33.1 million March offering and $52.8 million balance fund it into 2028](https://aibio.space/news/sol-gel-says-33-1-million-march-offering-52-8-million-balance-fund/)

Sol-Gel's first-quarter 2026 report shows $52.8 million in cash and securities at March 31 after a March offering of about $33.1 million, with revenue of $0.1 million and a net loss of $3.7 million. The company says the funds support operations into 2028.

## Latest Sol-Gel Technologies news

1. 2025-08-15 Listings [Sol-Gel reports $24.2 million in cash, expects runway into early 2027](https://aibio.space/news/sol-gel-reports-24-2-million-cash-expects-runway-early-2027/) Sol-Gel's second-quarter report shows $24.2 million in cash and securities at June 30, 2025, and net income of $11.6 million that came mostly from a one-time $16 million sale of U.S. product rights. The company's largest pipeline asset still has no results until the fourth quarter of 2026.
2. 2025-05-22 Listings [Sol-Gel Technologies regains Nasdaq minimum bid price compliance after extension](https://aibio.space/news/sol-gel-technologies-regains-nasdaq-minimum-bid-price-compliance-after/) Nasdaq confirmed on May 22, 2025 that the bid price deficiency matter is closed. The stock closed at $1.00 or more for 13 consecutive business days.

## Sol-Gel Technologies at a glance

- **Ticker**: SLGL

- **Listing**: NASDAQ

- **Country**: Israel

- **Cash, Dec 31, 2025**: $24.0 million

### Related companies

- [BioLineRX](https://aibio.space/companies/biolinerx/) TASE: BLRX
- [PRF Technologies](https://aibio.space/companies/prf-technologies/) NASDAQ: PRFX
- [NeuroSense Therapeutics](https://aibio.space/companies/neurosense-therapeutics/) NASDAQ: NRSN
- [Rekah Pharmaceutical Industry](https://aibio.space/companies/rekah-pharmaceutical-industry/) TASE: REKA
- [EPITOMEE MEDICAL LTD](https://aibio.space/companies/epitomee-medical/) TASE: EPIT
- [Redhill Biopharma](https://aibio.space/companies/redhill-biopharma/) NASDAQ: RDHL
- [SciSparc](https://aibio.space/companies/scisparc/) NASDAQ: SPRC
- [Entera Bio](https://aibio.space/companies/entera-bio/) NASDAQ: ENTX

### Also on NASDAQ

- [Twist Bioscience](https://aibio.space/companies/twist-bioscience/) TWST
- [Processa Pharmaceuticals](https://aibio.space/companies/processa-pharmaceuticals/) PCSA
- [Adaptive Biotechnologies](https://aibio.space/companies/adaptive-biotechnologies/) ADPT
- [BillionToOne](https://aibio.space/companies/billiontoone/) BLLN
- [Vir Biotechnology](https://aibio.space/companies/vir-biotechnology/) VIR
- [Evaxion](https://aibio.space/companies/evaxion/) EVAX

## Sol-Gel Technologies annual financials

| Line | FY2025 | FY2024 |
|---|---|---|
| Revenue | [$19.4 million](https://www.sec.gov/Archives/edgar/data/1684693/000117891326001552/) | [$11.5 million](https://www.sec.gov/Archives/edgar/data/1684693/000117891326001552/) |
| Research and development | [$22.8 million](https://www.sec.gov/Archives/edgar/data/1684693/000117891326001552/) | [$17.8 million](https://www.sec.gov/Archives/edgar/data/1684693/000117891326001552/) |
| Net income (loss) | [-$6.1 million](https://www.sec.gov/Archives/edgar/data/1684693/000117891326001552/) | [-$10.6 million](https://www.sec.gov/Archives/edgar/data/1684693/000117891326001552/) |
| Cash from operations | [$322,000](https://www.sec.gov/Archives/edgar/data/1684693/000117891326001552/) | [-$13.9 million](https://www.sec.gov/Archives/edgar/data/1684693/000117891326001552/) |
| Cash and equivalents | [$11.0 million](https://www.sec.gov/Archives/edgar/data/1684693/000117891326001552/) | [$19.5 million](https://www.sec.gov/Archives/edgar/data/1684693/000117891326001552/) |
| Short-term investments | [$13.0 million](https://www.sec.gov/Archives/edgar/data/1684693/000117891326001552/) | [$4.4 million](https://www.sec.gov/Archives/edgar/data/1684693/000117891326001552/) |

Latest balance sheet, Dec 31, 2025 (20-F): cash and equivalents $11.0 million, plus short-term investments of $13.0 million, $24.0 million in all.

Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice.

## Questions about Sol-Gel Technologies

Has Sol-Gel Technologies raised money recently?

Our latest story on this, dated May 28, 2026: "Sol-Gel says $33.1 million March offering and $52.8 million balance fund it into 2028". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/sol-gel-says-33-1-million-march-offering-52-8-million-balance-fund/).

Has Sol-Gel Technologies received a Nasdaq deficiency notice?

Our latest story on this, dated May 22, 2025: "Sol-Gel Technologies regains Nasdaq minimum bid price compliance after extension". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/sol-gel-technologies-regains-nasdaq-minimum-bid-price-compliance-after/).

What is the ticker symbol of Sol-Gel Technologies?

Sol-Gel Technologies Ltd. trades under the ticker SLGL on NASDAQ.

Where is Sol-Gel Technologies listed?

Sol-Gel Technologies Ltd. is listed on NASDAQ.

What is the SEC CIK of Sol-Gel Technologies?

The SEC Central Index Key (CIK) for Sol-Gel Technologies Ltd. is 1684693. Its filings are on SEC EDGAR.

How many shares does Sol-Gel Technologies have outstanding?

2,786,158 shares as of 2025-12-31, per the cover page of its 20-F filed 2026-03-19.

Which country or territory is Sol-Gel Technologies listed under?

Our directory records Sol-Gel Technologies Ltd. under Israel.

What does Sol-Gel Technologies do?

Our directory classifies Sol-Gel Technologies Ltd. as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline.

What is the ISIN of Sol-Gel Technologies?

The ISIN recorded for Sol-Gel Technologies Ltd. is IL0011417206.

Does aibio.space cover Sol-Gel Technologies?

aibio.space lists Sol-Gel Technologies Ltd. among 2,820 public biotech companies and publishes its news here as stories appear.

Where is Sol-Gel Technologies incorporated?

SEC records list its state or country of incorporation as L3.

What was Sol-Gel Technologies's revenue last year?

$19.4 million for the fiscal year ended Dec 31, 2025, as reported to the SEC.

Is Sol-Gel Technologies profitable?

Sol-Gel Technologies Ltd. reported a net loss of $6.1 million for the fiscal year ended Dec 31, 2025, and generated $322,000 of cash from operations, per its annual report to the SEC.

How much does Sol-Gel Technologies spend on research and development?

$22.8 million in the fiscal year ended Dec 31, 2025, per its annual report.

How much cash does Sol-Gel Technologies have?

$24.0 million in cash and short-term investments at Dec 31, 2025, per its 20-F.

## Investor discussion: Sol-Gel Technologies

Members talk about Sol-Gel Technologies (SLGL). Reader posts, not aibio.space reporting, and not investment advice.

Rules

1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information.
2. **Say whether you hold the stock.** Every post states long, short or no position.
3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you.
4. **No buy or sell calls and no price targets.**
5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them.
6. **No personal details and no spam.** No links at all for your first 7 days as a member.

Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion).

## Capital-markets timeline

Financings, listing notices, splits, legal actions and other investor events at Sol-Gel Technologies, newest first. Each line links the filing it comes from.

1. 2026-05-28 Financings Reported a financing. SEC Form 6-K. [Source](https://www.sec.gov/Archives/edgar/data/1684693/000117891326002963/exhibit_99-1.htm)
2. 2026-03-24 Financings Reported a financing. SEC Form 424B5. [Source](https://www.sec.gov/Archives/edgar/data/1684693/000117891326001626/zk2634907.htm)
3. 2026-03-19 Distress Reported substantial doubt about its ability to continue as a going concern. SEC Form 20-F. [Source](https://www.sec.gov/Archives/edgar/data/1684693/000117891326001552/zk2634571.htm)
4. 2025-12-17 Financings Reported a financing. SEC Form 6-K. [Source](https://www.sec.gov/Archives/edgar/data/1684693/000117891325004081/exhibit_99-1.htm)
5. 2025-08-15 Listings Reported a reverse stock split. SEC Form 6-K. [Source](https://www.sec.gov/Archives/edgar/data/1684693/000117891325002946/exhibit_99-1.htm)
6. 2025-05-22 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 6-K. [Source](https://www.sec.gov/Archives/edgar/data/1684693/000117891325001925/zk2533255.htm)
7. 2025-05-05 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 6-K. [Source](https://www.sec.gov/Archives/edgar/data/1684693/000117891325001578/exhibit_99-1.htm)
8. 2025-04-29 Financings Set up an at-the-market program to sell shares over time. SEC Form F-3. [Source](https://www.sec.gov/Archives/edgar/data/1684693/000117891325001513/zk2533072.htm)
9. 2025-04-01 Listings Reported a reverse stock split. SEC Form 6-K. [Source](https://www.sec.gov/Archives/edgar/data/1684693/000117891325001152/zk2532961.htm)
10. 2025-02-18 Listings Reported a reverse stock split. SEC Form 6-K. [Source](https://www.sec.gov/Archives/edgar/data/1684693/000117891325000533/exhibit_99-1.htm)
11. 2024-11-20 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 6-K. [Source](https://www.sec.gov/Archives/edgar/data/1684693/000117891324003782/exhibit_99-1.htm)
12. 2024-11-15 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 6-K. [Source](https://www.sec.gov/Archives/edgar/data/1684693/000117891324003727/exhibit_99-1.htm)

## Stock chart

Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open NASDAQ:SLGL on TradingView](https://www.tradingview.com/symbols/NASDAQ-SLGL/).

## SEC filings and registration

- **SEC name**: Sol-Gel Technologies Ltd.

- **CIK**: 1684693

- **Industry (SIC)**: Pharmaceutical Preparations (2834)

- **US tickers**: SLGL (Nasdaq)

- **State or country of incorporation**: L3

- **Fiscal year ends**: December 31

- **Filer category**: Non-accelerated filer

- **Business address**: 7 GOLDA MEIR ST., NESS ZIONA, 7403648

- **Phone**: 97289313433

- **Shares outstanding**: 2,786,158 as of 2025-12-31 (20-F filed 2026-03-19)

### Recent filings (8-K and 6-K are the company's own announcements)

- [6-K](https://www.sec.gov/Archives/edgar/data/1684693/000117891326004718/zk2636198.htm) filed 2026-10-06
- [6-K](https://www.sec.gov/Archives/edgar/data/1684693/000117891326004668/zk2636179.htm) filed 2026-09-30
- [6-K](https://www.sec.gov/Archives/edgar/data/1684693/000117891326004537/zk2636127.htm) filed 2026-09-17
- [6-K](https://www.sec.gov/Archives/edgar/data/1684693/000117891326004205/zk2635954.htm) filed 2026-08-20
- [6-K](https://www.sec.gov/Archives/edgar/data/1684693/000117891326002963/zk2635418.htm) filed 2026-05-28
- [6-K](https://www.sec.gov/Archives/edgar/data/1684693/000117891326001628/zk2634892.htm) filed 2026-03-24
- [424B5](https://www.sec.gov/Archives/edgar/data/1684693/000117891326001626/zk2634907.htm) filed 2026-03-24
- [20-F](https://www.sec.gov/Archives/edgar/data/1684693/000117891326001552/zk2634571.htm) filed 2026-03-19

Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001684693), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices.

## Listing details

Sol-Gel Technologies Ltd. is a public biotech or pharmaceutical company listed on NASDAQ under the ticker SLGL, recorded under Israel. The directory classifies it as Pharmaceuticals: Major. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them.

- **Company**: Sol-Gel Technologies Ltd.

- **Ticker**: SLGL

- **Listing**: NASDAQ

- **Country or territory**: Israel

- **Business scope**: Pharmaceuticals: Major

- **ISIN**: IL0011417206

- **Last quote in directory**: 2026-10-21

- **Directory source**: [Listing page](https://www.tradingview.com/symbols/NASDAQ-SLGL/)

Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/).

Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/).

Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update)

---
Source page: https://aibio.space/companies/sol-gel-technologies/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Sol-Gel Technologies (SLGL) news: offering and Nasdaq notice", 2026-10-31, https://aibio.space/companies/sol-gel-technologies/